Current Report Filing (8-k)
April 13 2018 - 4:37PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 12, 2018
CATALYST BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-51173
|
|
56-2020050
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
611 Gateway Blvd., Suite 710
South San Francisco, California
|
|
94080
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(650) 8710761
Registrants telephone number, including area code
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934 (§
240.12b-2
of this
chapter).
Emerging growth company ☐
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
On April 12, 2018, Catalyst Biosciences, Inc. (the Company) issued a
press release announcing that the Korean Ministry of Food and Drug Safety has approved the addition of a sixth cohort to the Companys Phase 1/2 trial of CB 2679d/ISU304 in individuals with hemophilia B, a copy of which is attached as Exhibit
99.1 to this Current Report on Form
8-K
and is incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
CATALYST BIOSCIENCES, INC.
|
|
|
|
|
Date: April 12, 2018
|
|
|
|
|
|
/s/ Fletcher Payne
|
|
|
|
|
|
|
Fletcher Payne
|
|
|
|
|
|
|
Chief Financial Officer
|
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024